International Consensus Guidelines Recommend WES/WGS as First-Line or Early Diagnostic Testing

International Consensus Guidelines Recommend WES/WGS as First-Line or Early Diagnostic Testing

In pediatric neurodevelopmental disorders, developmental delay (DD), intellectual disability (ID), and autism spectrum disorder (ASD) are among the most common yet genetically complex conditions encountered in clinical practice.

Many affected children present early in life with speech delay, motor delay, learning difficulties, seizures, hypotonia, dysmorphic features, congenital anomalies, or multisystem involvement. However, traditional stepwise evaluations - such as chromosome studies, metabolic tests, single-gene testing, or repeated specialist referrals - may still fail to provide a definitive answer, leading families into a long and exhausting "diagnostic odyssey."

In recent years, international clinical guidelines and expert consensus have increasingly supported Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) as early-line, and in many scenarios first-line, genetic testing strategies for children with DD, ID, ASD, and broader neurodevelopmental disorders.

‍

A shift toward earlier genomic testing

The 2021 ACMG evidence-based clinical guideline states that exome or genome sequencing should be considered as a first- or second-tier test for pediatric patients with congenital anomalies, developmental delay, or intellectual disability. A 2019 multidisciplinary consensus statement in Genetics in Medicine also concluded that exome sequencing can serve as a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. The 2023 position statement from the Canadian College of Medical Geneticists further includes global developmental delay, intellectual disability, and autism spectrum disorder within the scope of recommended genetic and metabolic evaluation.

Together, these recommendations reflect an important change in clinical thinking: WES and WGS should not always be viewed only as "last-resort" tests after years of uncertainty. In appropriate clinical situations, they may be considered earlier in the diagnostic process.

Why WES and WGS matter in neurodevelopmental disorders

The clinical value of WES and WGS is not simply the ability to test "more genes." Rather, these technologies provide a systematic approach to evaluate thousands of genes associated with neurodevelopmental disorders in a single test.

WES focuses on the exome, the protein-coding regions of the genome where many known disease-causing variants are found. WGS provides an even broader view by analyzing the genome more comprehensively, including coding and non-coding regions as well as certain variant types that may be difficult to detect through more limited approaches.

‍

Depending on the testing platform and analysis design, WES/WGS may help identify:

• De novo variants

• Inherited variants

• X-linked disorders

• Compound heterozygous variants

• Selected copy-number variants or structural variants

• Genetic causes associated with congenital anomalies or multisystem presentations

This broader diagnostic approach may help clinicians connect a child's clinical features with a possible molecular explanation more efficiently.

‍

How ACT Genomics supports WES and WGS testing

To support clinicians and families facing complex or unresolved cases, ACT Genomics provides both ACTExome and ACTInherit as genomic testing options.

ACTExome is ACT Genomics' Whole Exome Sequencing service. It is designed to evaluate the protein-coding regions of the genome and may be considered for individuals with suspected hereditary disease, unexplained developmental delay, intellectual disability, autism spectrum disorder, congenital anomalies, or inconclusive results from previous testing.

ACTInherit is ACT Genomics' Whole Genome Sequencing service. It provides a broader genome-wide analysis and may be considered when a more comprehensive genomic view is needed, especially in complex cases where previous testing has not identified the underlying cause.

Together, ACTExome and ACTInherit support different levels of genomic analysis, allowing clinicians to select the approach that best fits the patient's clinical presentation, prior testing history, and diagnostic needs.

‍

Why earlier molecular diagnosis matters

For clinicians, an early molecular diagnosis can help clarify the disease entity, guide prognosis, inform clinical surveillance, and reduce unnecessary repeated investigations. This may be especially important when children present with seizures, cardiac involvement, renal abnormalities, ophthalmologic concerns, developmental regression, or other systemic complications.

For families, a genetic diagnosis can also support recurrence-risk assessment, parental carrier-status evaluation, reproductive planning, and risk assessment for other family members.

In this sense, genetic diagnosis is not simply a test result. It can become the foundation for more informed care planning and long-term disease management.

‍

Who may benefit from WES/WGS?

WES or WGS may be worth discussing with a healthcare professional or genetic counseling team when a child has:

• Unexplained developmental delay

• Intellectual disability

• Autism spectrum disorder with additional clinical features

• Seizures or epilepsy

• Abnormal muscle tone

• Developmental regression

• Congenital anomalies

• Dysmorphic features

• Suspected hereditary disease

• Positive family history

• Multisystem involvement

• Inconclusive results after previous genetic testing

‍

Shortening the diagnostic odyssey

For children and families living with unanswered questions, time matters. The earlier a molecular diagnosis is identified, the earlier clinicians may be able to provide more tailored care recommendations, evaluate disease-specific risks, and support long-term planning.

When combined with detailed phenotyping, ACMG/ClinGen-based variant interpretation, and professional genetic counseling, WES and WGS can help shorten the diagnostic odyssey and support more precise diagnosis, clearer care direction, and long-term management strategies. The answer may not be missing. It may simply not have been seen yet.

If you or a family member has experienced a long diagnostic journey, received inconclusive genetic test results, or is suspected of having a hereditary condition, speak with a healthcare professional about whether ACTExome Whole Exome Sequencing or ACTInherit Whole Genome Sequencing may be appropriate.

To learn more, please contact ACT Genomics' Genetic Counseling team: service@actgenomics.com

‍

Disclaimer

This content is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Any testing or treatment decisions should be made by qualified healthcare professionals based on each patient's individual condition and the latest clinical evidence.

‍

References

1. Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the ACMG. Genetics in Medicine. 2021;23(11):2029-2037.
2. Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genetics in Medicine. 2019;21(11):2413-2421.
3. Carter MT, Srour M, Tétreault M, et al. Genetic and metabolic investigations for neurodevelopmental disorders: position statement of the Canadian College of Medical Geneticists. Journal of Medical Genetics. 2023;60(6):523-532.

‍

‍